Aedicell


AediCell provides smarter solutions to wound care by delivering safe, effective, and easy-to-use products at a lower overall cost. Their mission is to improve wound healing outcomes through innovative technologies utilizing human placental tissues and other biological materials. They focus on providing products like Dermavest® that treat damaged tissue in ulcers and wounds, leveraging their advanced technology to preserve important cell attachment proteins, growth factors, and cytokines.

Industries

biotechnology
manufacturing
medical

Nr. of Employees

small (1-50)

Aedicell

Rochester, New York, United States, North America


Products

Placental-derived wound matrix product

A wound therapy product derived from human placental tissues (amnion/chorion, umbilical cord, and placental disk) intended for treatment of ulcers and chronic wounds; manufactured to preserve bioactive proteins, growth factors, and cytokines.


Services

Sampling consultation and product demonstration

On-request demonstrations and sampling consultations for clinicians to evaluate placental-derived wound therapy products.

Reimbursement analysis and consulting

Assessment of reimbursement opportunities and coding considerations for clinical practices using placental-derived wound therapies.

Expertise Areas

  • Wound care using placental-derived biomaterials
  • Tissue processing and preservation of bioactive factors
  • Acellular tissue scaffold development
  • Clinical evidence generation for wound therapies
  • Show More (2)

Key Technologies

  • Placental tissue-derived matrices
  • Acellular tissue scaffold preparation
  • Tissue preservation methods for proteins and cytokines
  • Biologic wound matrix formulation
  • Show More (1)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.